开发和优化含有Myricetin的可吸入微球,用于治疗COPD.
Suhas Shivaji Siddheshwar1, Darshana Jagtap2, Someshwar Dattatraya Mankar2
1Department of Pharmaceutics, Pravara Rural College of Pharmacy, Loni, Maharashtra, India. drssiddheshwar@gmail.com.
Pharmaceutical research
|November 11, 2025
概括
研究人员开发了优化的含有myricetin的可吸入微球,用于慢性阻塞性肺病 (COPD) 治疗中持续的肺输送. 这种新型配方表现出显著的支气管扩张活性和改善肺部沉积,提供了一个有前途的治疗选择.
科学领域:
- 药品制造 药品制造 药品制造
- 药物运输 药物运输 药物运输
- 呼吸系统医学 呼吸系统医学
背景情况:
- 慢性阻塞性肺病 (COPD) 需要有效和持续的药物治疗,以改善患者的治疗结果.
- 肺部药物输送系统的目的是提高治疗效率并减少全身副作用.
- 瑞是一种天然的黄类化合物,对呼吸系统疾病具有潜在的治疗特性.
研究的目的:
- 开发和优化充满myricetin的可吸入微球,用于持续的肺部输送.
- 评估myricetin装载微球的物理化学,体外释放和空气动力学特性.
- 在临床前模型中评估优化配方的支气管扩张活性.
主要方法:
- 含有myricetin的微球是通过离子转变凝和3^2全因数设计使用凝和藻酸盐制备的.
- 特性包括粒子大小,形态,捕获效率,泽塔潜力,体外药物释放和空气动力学性能 (双重影响者).
- 稳定性研究是在加速和实时条件下进行的. 使用山羊气管链模型评估了支气管扩张活性,并与无水的西奥菲林相比较.
主要成果:
- 优化的配方 (DF4) 显示了球形形态,最佳颗粒大小 (7.72μm),高捕获效率 (72.84%),以及良好的体稳定性 (负泽塔潜力).
- 观察到出色的空气动力学特性 (FPF 31.71%),持续释放超过12小时,并在6个月内观察到显著的稳定性.
- 达到了显著的支气管扩张活性 (63.47%的放松在25μg/ml),与无水性神素相比,疗效约为80.8%.
结论:
- 优化的含有myricetin的可吸入微球代表了COPD管理的有前途的肺输送系统.
- 该配方提供持续释放,改善肺部沉积和显著的支气管扩张作用,可能减少剂量频率并提高患者的服药性.
- 进一步的体内研究有必要支持临床转化,以改善COPD患者的治疗结果.
相关概念视频
Inhaled Medications
717
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
717
COPD: Management Using Bronchodilators and Corticosteroids
709
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
709
Chronic Obstructive Pulmonary Disease-V: Management
3.1K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.1K
Drugs Used in Lower Respiratory Disorders: Overview
1.0K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.0K
Antiasthma Drugs: Methylxanthines
1.6K
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
1.6K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
1.5K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.5K


